BRISTOL MYERS SQUIBB CO

Drug pipeline (272)

Asset	Stage	Revenue	Trials	Status
Apixaban	approved	$4.5BQ2 2026	29	approved
NIVOLUMAB	phase2	$3.1BQ2 2026	221	active
ABATACEPT	approved	$1.0BQ2 2026	52	approved
IPILIMUMAB	phase1_2	$769.0MQ2 2026	128	active
Lisocabtagene Maraleucel	approved	$484.0MQ2 2026	8	approved

Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.

Clinical trials (1724)

NCT ID	Phase	Status	Start	Completion	Sponsor name	Title
NCT01733875	phase1	completed	2012-11-01	2013-10-09	Celgene	2-part Study to Assess Safety, Pharmacokinetics & Pharmacodynamics of CC-220 & Effect of Food on CC-220 in Healthy Subjects
NCT02034773	phase1	completed	2013-05-01	2013-12-01	Celgene Corporation	3-part Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Multiple Doses of CC-220 and Relative Bioavailability of a Formulated CC-220 Capsule
NCT02323594	phase1	completed	2014-12-01	2015-02-01	Bristol-Myers Squibb	A Bioequivalence Study of Daclatasvir Tablets and Bioavailability Studies of Daclatasvir and Asunaprevir
NCT02156076	phase2	terminated	2014-07-25	2016-06-01	Bristol-Myers Squibb	A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation
NCT04151563	phase1_2	withdrawn	2021-04-15	2023-12-17	Bristol-Myers Squibb	A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy

FDA applications (248)

Application

Approved

Type

Applicant

Products

NDA 221075

2026-08-13

NDA

BRISTOL MYERS SQUIBB CO

NDA 220073

2025-04-17

NDA

BRISTOL MYERS SQUIBB CO

BLA 761381

2024-12-27

BLA

Bristol-Myers Squibb Company

NDA 216158

2024-09-26

NDA

BRISTOL-MYERS SQUIBB CO

NDA 218213

2023-11-15

NDA

BRISTOL MYERS SQUIBB CO